In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopharma Quarterly Dealmaking Statistics, Q3 2017

A look at financing, M&A and alliance activity July–September 2017

Executive Summary

Third-quarter biopharma financing, which totaled $12.5 billion, was dominated by follow-on public offerings, which represented virtually half the value. Acquisition activity was headlined by a major move by Gilead in the CART market. Five alliances were signed worth over $1 billion, led by a partnership between two key players, Merck & Co. and AstraZeneca.

Advertisement

Related Content

UK's Nightstar NASDAQ Listing Backs British Biotech Build-Up Strategy
Disappointed, Yes, But Roivant's Not Roiled By Axovant's Alzheimer's Failure
SpringWorks Launches With $103m, Four Pfizer Drugs And A Focus On Underserved Patients
The Next Roivant Or Fortress? BridgeBio Raises $135m To Spin Out New Companies
Rigontec Buy Adds RNA Tech To Merck & Co IO Portfolio
What's Next On Gilead's Shopping List
Gilead Makes Cell Therapy The Base Of Its Oncology Platform With Kite Buy
An Inflammatory Deal: Bristol Commits Up To $2.3bn To Buy IFM Therapeutics
A Whopper Of A Deal: AZ Hands Half Of Lynparza To Merck
Will Mitsubishi's High Offer Price For CNS Target NeuroDerm Deter Others?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV005216

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel